Market Events and Forecast | Ophthalmology | US/EU5 | 2021
In 2019, sales of branded biologics in ophthalmology reached almost $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection; biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these two key reference brands and their biosimilars by molecule and region.
Related Market Assessment Reports
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
